FIGURE

Fig. 2

ID

ZDB-FIG-250327-2

Publication

Hua et al., 2025 - Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance

Other Figures

All Figure Page

Back to All Figure Page

Fig. 2

Effects of combination therapy with anlotinib and osimertinib on NSCLC cells in vitro. A CCK-8 assay was conducted to explore the proliferative capacities of (A) H1975, (B) PC9, (C) H1975-OR, and (D) PC9-OR cells, pre-treated with the NC, osimertinib monotherapy (1 µM), anlotinib monotherapy (3 µM), and a combination of anlotinib (3 µM) and osimertinib (1 µM) for 72 h. An MTT test was conducted to determine cell viability in (E) H1975-OR and (F) PC9-OR cells treated with different concentrations of osimertinib monotherapy or the combination of anlotinib (3 µM) and osimertinib. P values were calculated by two-way ANOVA analysis; ***, P<0.001; NS, not significant. OD, optical density; NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib; NSCLC, non-small cell lung cancer; CCK-8, Cell Counting Kit-8; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide; ANOVA, analysis of variance.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Transl Lung Cancer Res